Click to search for your profile
Click to search for condition or expert
Click to open main menu
Save Condition
Bookmark
Share
Share
Condition
Clinical Trials for
Urothelial Cancer
Overview
Find a Doctor
Latest Advances
Clinical Trials
Clinical Trials
Search for trials
Filter
Clinical Trial
Status:
Not yet recruiting
Phase:
Phase 1
Intervention Type:
Drug
Participants:
24
Start Date:
July 2021
Sacituzumab Govitecan Plus Enfortumab Vedotin for Metastatic Urothelial Carcinoma Progressing on Platinum-based Chemotherapy and PD1/L1 Inhibitors: the Double Antibody Drug Conjugate (DAD) Phase I Trial
Clinical Trial
Status:
Not yet recruiting
Phase:
Phase 2
Intervention Type:
Drug, Procedure
Participants:
30
Start Date:
June 2021
A Multicenter, Single-Arm Open Label Phase II Trial of Cryoablation in Combination With Pembrolizumab in Patients With Metastatic Urothelial Carcinoma
Search for trials
Clinical Trial
Status:
Not yet recruiting
Participants:
40
Start Date:
May 2021
A Pilot Study to Assess the Concordance of Genomic Alterations Between Urine and Tissue to Develop Precision Medicine-Based Immunotherapy Approaches in High-Risk NMIBC Patients
Clinical Trial
Status:
Recruiting
Phase:
Phase 1/Phase 2
Intervention Type:
Drug, Biological
Participants:
18
Start Date:
April 12, 2021
ATTAMAGE-A1.: Phase I/II Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity MAGE-A1-Specific T-Cell Receptor (TCR) Combined With Atezolizumab in Patients With Metastatic MAGE-A1 Expressing Cancer
Clinical Trial
Status:
Not yet recruiting
Phase:
Phase 2
Intervention Type:
Drug
Participants:
90
Start Date:
March 31, 2021
An Open-Label, Randomized, Phase 2, Umbrella Study of Various Neoadjuvant Therapies for Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Cisplatin-Ineligible or Refuse Cisplatin Therapy and Undergoing Radical Cystectomy
Clinical Trial
Status:
Not yet recruiting
Phase:
Phase 2
Intervention Type:
Drug
Participants:
140
Start Date:
March 2021
Phase II Randomized Study of Neoadjuvant Durvalumab (MEDI4736) Alone Versus Durvalumab (MEDI4736) With Olaparib (AZD2281) in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy
Clinical Trial
Status:
Recruiting
Phase:
Phase 3
Intervention Type:
Drug, Procedure
Participants:
632
Start Date:
February 19, 2021
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (LG IR NMIBC)
Clinical Trial
Status:
Recruiting
Phase:
Phase 3
Intervention Type:
Drug
Participants:
465
Start Date:
February 16, 2021
A Phase III Randomized Trial of Eribulin (NSC #707389) With or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
Clinical Trial
Status:
Not yet recruiting
Phase:
Phase 1
Intervention Type:
Drug
Participants:
68
Start Date:
February 1, 2021
A Phase I Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Plus Gemcitabine in Advanced Solid Tumors With an Emphasis on Urothelial Carcinoma
Clinical Trial
Status:
Recruiting
Phase:
Phase 2
Intervention Type:
Drug
Participants:
69
Start Date:
February 2021
An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Tislelizumab Combined With Nab-Paclitaxel Before Cystectomy or Complete TURBT for Patients With Muscle-invasive Urothelial Bladder Cancer.
Clinical Trial
Status:
Not yet recruiting
Phase:
Phase 2
Intervention Type:
Drug
Participants:
63
Start Date:
February 2021
An Open Label, Single-arm, Phase 2 Study of Tislelizumab Combined With Nab-Paclitaxel for Patients With High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable
Clinical Trial
Status:
Recruiting
Phase:
Phase 1/Phase 2
Intervention Type:
Drug
Participants:
45
Start Date:
February 1, 2021
A Multi-center Open-label, Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-192 in Patients With Advanced Solid Tumors and FGFR Gene Alterations
Showing 1-12 of 252
Next